DEXLANSOPRAZOLE
| Brand name | DEXILANT |
|---|---|
| Active ingredient | DEXLANSOPRAZOLE |
| Strength | 60MG |
| Dosage form | CAPSULE, DELAYED RELEASE |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | January 2009 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 9233103 | March 2032 | use U-1805 |
| 8173158*PED | September 2030 | — |
| 8173158 | March 2030 | use U-949 |
| 8871273 | January 2028 | product |
| 8105626*PED | March 2027 | — |
| 7790755*PED | February 2027 | — |
| 8105626 | September 2026 | product |
| 7790755 | August 2026 | product |
| 8461187*PED | July 2026 | — |
| 9011926 | February 2026 | product |
| 8461187 | January 2026 | product |
| 9238029 | January 2026 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.